Systemic lupus erythematosus

Common Name(s)

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by {93:Oishi et al., 2008}). Genetic Heterogeneity of Systemic Lupus Erythematosus An autosomal recessive form of systemic lupus erythematosus (SLEB16; {614420}) is caused by mutation in the DNASE1L3 gene ({602244}) on chromosome 3p14.3. See MAPPING and MOLECULAR GENETICS sections for a discussion of genetic heterogeneity of susceptibility to SLE.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Systemic lupus erythematosus" for support, advocacy or research.

Logo
International Foundation for Autoimmune Arthritis

We are committed to eliminating the adversity caused by autoimmune arthritis by uniting resources that will raise global awareness, providing wellness education and support, and conducting patient-centered research that will improve the quality of life for those affected by these diseases.

Last Updated: 18 Sep 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Systemic lupus erythematosus" for support, advocacy or research.

Logo
International Foundation for Autoimmune Arthritis

We are committed to eliminating the adversity caused by autoimmune arthritis by uniting resources that will raise global awareness, providing wellness education and support, and conducting patient-centered research that will improve the quality of life for those affected by these diseases.

http://www.ifautoimmunearthritis.org

Last Updated: 18 Sep 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Systemic lupus erythematosus" returned 4590 free, full-text research articles on human participants. First 3 results:

Patterns of foot complaints in systemic lupus erythematosus: a cross sectional survey.
 

Author(s): Simon J Otter, Sunil Kumar, Peter Gow, Nicola Dalbeth, Michael Corkill, Maheswaran Rohan, Kevin A Davies, Sam Pankathelam, Keith Rome

Journal:

 

Foot complaints are common in inflammatory arthropathies such as rheumatoid arthritis and cause considerable disability. However, little is published about the nature and extent of foot complaints in systemic lupus erythematosus (SLE). We aimed to explore foot complaints among people ...

Last Updated: 23 Mar 2016

Go To URL
H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus.
 

Author(s): Zhe Zhang, Lihua Shi, Noor Dawany, Judith Kelsen, Michelle A Petri, Kathleen E Sullivan

Journal:

 

The autoimmune disease systemic lupus erythematosus (SLE) has a modified epigenome with modified tri-methylation of histone H3 lysine 4 (H3K4me3) at specific loci across the genome. H3K4me3 is a canonical chromatin mark of active transcription. Recent studies have suggested that H3K4me3 ...

Last Updated: 3 Feb 2016

Go To URL
Evans syndrome and its link with systemic lupus erythematosus.
 

Author(s): Satish Mendonca, Sachin Srivastava, Rajan Kapoor, Devika Gupta, Pooja Gupta, M L Sharma

Journal: Saudi J Kidney Dis Transpl. 2016 Jan;27(1):147-9.

 

Evans syndrome is a rare syndrome associated with the presence of autoimmune hemolytic anemia and simultaneous or sequential development of thrombocytopenia. It was first described by Evan and Duane in 1951. It is one of the rare presenting features of autoimmune disorders, especially ...

Last Updated: 20 Jan 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Systemic lupus erythematosus" returned 508 free, full-text review articles on human participants. First 3 results:

Eosinophilic Granulomatosis With Polyangiitis With Thrombotic Microangiopathy: Is Simultaneous Systemic Lupus Erythematosus Associated With Clinical Manifestations?: A Case Report and Review of the Literature.
 

Author(s): Shoichi Fukui, Naoki Iwamoto, Sosuke Tsuji, Masataka Umeda, Ayako Nishino, Yoshikazu Nakashima, Takahisa Suzuki, Yoshiro Horai, Tomohiro Koga, Shin-Ya Kawashiri, Kunihiro Ichinose, Yasuko Hirai, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Naóe Kinoshita, Atsushi Kawakami

Journal: Medicine (Baltimore). 2015 Nov;94(45):e1943.

 

Eosinophilic granulomatosis with polyangiitis (EGPA) is one of the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, which is characterized by vasculitis of the small to medium-sized vessels. On the contrary, thrombotic microangiopathy (TMA) is a life-threatening condition ...

Last Updated: 12 Nov 2015

Go To URL
Is B Cell-Targeted Therapy Effective in Systemic Lupus Erythematosus?
 

Author(s): Daphna Paran, Yaakov Naparstek

Journal: Isr. Med. Assoc. J.. 2015 Feb;17(2):98-103.

 

In the past decade we have witnessed a dramatic change in the management of autoimmune diseases, such as rheumatoid arthritis, due to the development of new biologic drugs designed to target key mediators in the autoimmune process. However, the development of similar target-specific ...

Last Updated: 30 Jul 2015

Go To URL
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
 

Author(s): Thomas Dörner, Anthony Shock, David M Goldenberg, Peter E Lipsky

Journal: Autoimmun Rev. 2015 Dec;14(12):1079-86.

 

Epratuzumab is a B-cell-directed non-depleting monoclonal antibody that targets CD22. It is currently being evaluated in two phase 3 clinical trials in patients with systemic lupus erythematosus (SLE), a disease associated with abnormalities in B-cell function and activation. The ...

Last Updated: 30 Oct 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of Systemic Lupus Erythematosus
 

Status: Recruiting

Condition Summary: Systemic Lupus Erythematosus

 

Last Updated: 11 Mar 2016

Go to URL
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
 

Status: Not yet recruiting

Condition Summary: Systemic Lupus Erythematosus

 

Last Updated: 11 Dec 2015

Go to URL
GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus
 

Status: Recruiting

Condition Summary: Systemic Lupus Erythematosus (SLE)

 

Last Updated: 24 Mar 2016

Go to URL